porno izle
porno
asyabahis
women desperate to piss ava addams mom porn sa akin ang gabi
sisli escort mecidiyekoy escort

Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



Maggie McConnell's Articles

Arecor’s Partner Inhibrx Exercises Its Option To License A New Formulation Developed By Arecor In Accordance With The Terms Of Formulation Development Agreement

Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™.   This is the first license under a multi-product development agreement between Inhibrx and Arecor.

Arecor Announces Publication Of Phase I Data For AT247 In Diabetes Care

Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate.

Arecor: First Patient Dosed in Phase I Clinical Trial of Ultra-concentrated Rapid Acting Insulin Candidate, at 278, for Diabetes

Arecor Limited , the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278. 

ARECOR to Present at EASD 2020 - Oral Presentation of Phase I Clinical Trial of AT247, A Novel Ultra Rapid Acting Insulin

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart, NovoRapid®, and fast insulin aspart, Fiasp®, has been selected for oral presentation at the upcoming European Association for the Study of Diabetes (EASD) virtual meeting which will be held from 21-25 September 2020.  Abstract #55 is available online.

Arecor Presents Positive Results for the First Phase I Clinical Trial of AT247, a Novel Ultra-Rapid Acting Insulin

Arecor Presents Positive Results for the First Phase I Clinical Trial of AT247, a Novel Ultra-Rapid Acting Insulin.  AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®

Arecor announces the oral presentation of the first Phase I Clinical Trial of AT247, a novel Ultra Rapid Insulin Formulation, at the American Diabetes Association 80th Scientific Sessions

Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes Association 80th Scientific Sessions - Virtual (ADA) meeting which will be held from 12-16 June 2020.  Abstract #231-OR will be available online from 14 June 2020

Arecor Extends Multi-Product Collaboration with Clinical Stage Biotech

Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has extended its multi-product collaboration with a US-based clinical stage biotechnology company.  Under the collaboration, Arecor will leverage its Arestat™ technology to develop liquid formulations of two proprietary novel products in oncology and a rare genetic orphan condition.

Arecor Achieves Second License Milestone Payment From Global Pharmaceutical Partner

Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.

Arecor to participate At PEPTalk 2020’s Protein Science Week In San Diego, CA, USA

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces Dr Jan Jezek, Chief Scientific Officer, will present at PEPTalk 2020, in San Diego, California, USA on 20-24 January 2020.

Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology

Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into an exclusive agreement to co-develop a new, ready-to-use injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc.

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.